Emil Frei, M.D.
Richard & Susan Smith Disting. Professor of Med., Department of Medicine, Harvard Medical School
Physician-in-Chief, Emeritus, Cancer Pharmacology and Adult Oncology, Dana-Farber Cancer Institute
Contact Info
Emil Frei
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1216
Phone: 617-632-3556
Fax: 617-632-5775
emil_frei@dfci.harvard.edu
Administrative Assistant
Cancer Pharmacology and Adult Oncology
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-4677
Fax: 617-632-5775
kathleen_mccollum@dfci.harvard.edu
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: Dana 1216
Phone: 617-632-3556
Fax: 617-632-5775
emil_frei@dfci.harvard.edu
Assistant
Kathleen McCollumAdministrative Assistant
Cancer Pharmacology and Adult Oncology
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Phone: 617-632-4677
Fax: 617-632-5775
kathleen_mccollum@dfci.harvard.edu
DF/HCC Program Affiliation
Translational Pharmacology and Early Therapeutic TrialsCancer Cell Biology
Research Abstract
I am particularly interested in novel approaches to combination, dose and new agents in the construct of modeling and clinical trials, e.g., holotherapy. In addition, my research is focused on the oxygen effect on dose, the pharmacokinetics of mesothelioma, and short term drug resistance.Publications
- Frei E, Ara G, Teicher B, Bunnell C, Richardson P, Wheeler C, Tew K, Elias A.Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - effect of sequence.Cancer Chemother Pharmacol 2000;45(3):239-46.
10663642
